BioCentury
ARTICLE | Finance

Strong investor demand for InnoCare on HK exchange despite pandemic concerns

March 20, 2020 12:50 AM UTC
Updated on Mar 20, 2020 at 1:49 PM UTC

Despite ongoing turbulence in the global financial markets, strong demand by local investors enabled InnoCare to price its IPO on the Hong Kong exchange's biotech chapter at the top of its proposed range, valuing the company at HK$11.2 billion (US$1.4 billion).

Last week, InnoCare Pharma Ltd. (HKEX:9969) initially offered to sell 25 million shares to Hong Kong investors and 225.3 million shares to the international community at HK$8.18-HK$8.95. ...

BCIQ Company Profiles

InnoCare Pharma Ltd.

BCIQ Target Profiles

Bruton's tyrosine kinase (Btk)